A comprehensive view of eli lilly & co.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves Eli Lilly’s oral Olumiant as a standalone COVID-19 treatment for hospitalized adult patients using supplemental oxygen or ventilation; Olumiant has treated over one million patients with sales up from US$437.0M in 2019 to US$1.1B in 2021
Published: May 12, 2022 by FiercePharma
FDA approves BLA 125521 for Eli Lilly’s Taltz injectable containing ixekizumab 80 mg/mL in one formulation to treat autoimmune disease; the drug is available by prescription only and has no therapeutic equivalents
Published: May 12, 2022 by US Food and Drug Administration News (CBNB Abstracts)
Phase 3 study shows Lilly’s injectable tirzepatide helped two-thirds of participants reduce body weight by at least 20%; tirzepatide is first investigational medicine to deliver more than 20% weight loss on average in a phase 3 study
Published: May 03, 2022 by Eli Lilly & Co.
Eli Lilly reports Q1 net profit up 40% from a year ago to US$1.9B, with revenue up 15% year-over-year to US$7.8B; Q1 COVID-19 antibody drug sales up at US$1.47B from US$810.1M a year ago, as company raises 2022 revenue guidance to US$28.8B to US$29.3B
Published: May 02, 2022 by SeeNews Pharmaceuticals
Biopharmaceutical firm Innovent partners with Eli Lilly to distribute intravenous gastric, liver cancer drugs Cyramza ramucirumab, Retsevmo selpercatinib, Pirtobrutinib in China; gastric and liver cancers affect nearly 900,000 patients annually in China
Published: March 29, 2022 by PR Newswire

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count